WOOJUNG BIO, Inc.

KOSDAQ:A215380 Stock Report

Market Cap: ₩42.1b

WOOJUNG BIO Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for WOOJUNG BIO.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Life Sciences earnings growth23.5%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Jan 29

WOOJUNG BIO, Inc. (KOSDAQ:215380) Shares Fly 34% But Investors Aren't Buying For Growth

WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) shares have had a really impressive month, gaining 34% after a shaky period...
Analysis Article • Dec 27

Health Check: How Prudently Does WOOJUNG BIO (KOSDAQ:215380) Use Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Nov 04

WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Share Price Is Matching Sentiment Around Its Revenues

With a price-to-sales (or "P/S") ratio of 0.9x WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) may be sending very bullish signals...
Analysis Article • Aug 13

Is WOOJUNG BIO (KOSDAQ:215380) A Risky Investment?

KOSDAQ:A215380 1 Year Share Price vs Fair Value Explore WOOJUNG BIO's Fair Values from the Community and select yours...
Analysis Article • Jun 12

WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Price Is Right But Growth Is Lacking After Shares Rocket 26%

WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) shares have had a really impressive month, gaining 26% after a shaky period...
Analysis Article • Dec 09

WOOJUNG BIO, Inc.'s (KOSDAQ:215380) 27% Dip In Price Shows Sentiment Is Matching Revenues

The WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) share price has fared very poorly over the last month, falling by a substantial...
Analysis Article • Oct 14

Why Investors Shouldn't Be Surprised By WOOJUNG BIO, Inc.'s (KOSDAQ:215380) 30% Share Price Plunge

The WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) share price has softened a substantial 30% over the previous 30 days, handing...
Analysis Article • Aug 16

WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Shares Bounce 43% But Its Business Still Trails The Industry

WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) shareholders have had their patience rewarded with a 43% share price jump in the...
Analysis Article • Jun 14

Revenues Working Against WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Share Price Following 26% Dive

Unfortunately for some shareholders, the WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) share price has dived 26% in the last...
Analysis Article • May 23

Is WOOJUNG BIO (KOSDAQ:215380) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as WOOJUNG BIO has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A215380 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202640,304-3,677-3,821-3,737N/A
12/31/202537,587-5,547-890-630N/A
9/30/202537,123-3,723-4,461-4,047N/A
6/30/202536,596-4,140-3,444-2,872N/A
3/31/202541,355-250-963-460N/A
12/31/202443,200225-1,436-1,126N/A
9/30/202449,1362,8924,3704,959N/A
6/30/202444,7531,1819601,525N/A
3/31/202440,667-2,822-248242N/A
12/31/202338,616-5,054-4,116-3,222N/A
9/30/202331,366-4,927-5,914-2,691N/A
6/30/202336,457-3,037-9,014-3,605N/A
3/31/202341,790-4,804-9,042-990N/A
12/31/202246,918-1,880-9,0072,502N/A
9/30/202243,584-6,582-14,366-1,296N/A
6/30/202243,180-5,134-20,960515N/A
3/31/202235,409-3,197-29,6154,639N/A
12/31/202131,238-1,926-34,9021,728N/A
9/30/202134,042-3,515-37,1121,099N/A
6/30/202129,760-12,432-29,625985N/A
3/31/202131,702-11,682-23,788-3,460N/A
12/31/202037,344-10,879-25,213-8,575N/A
9/30/202036,141-8,772-16,835-8,412N/A
6/30/202037,3432,578-12,425-5,252N/A
3/31/202038,980770-5,713-3,024N/A
12/31/201932,290280N/A209N/A
9/30/201932,016-651N/A236N/A
6/30/201930,400-3,648N/A-3,211N/A
3/31/201926,507-2,451N/A-7,393N/A
12/31/201823,758-4,617N/A-484N/A
9/30/201824,213-4,025N/A-621N/A
6/30/201825,433-3,782N/A1,543N/A
3/31/201828,077-8,947N/A1,631N/A
12/31/201728,932-6,921N/A-2,376N/A
9/30/201726,053-5,764N/A-3,445N/A
6/30/201726,740-5,151N/A-2,308N/A
3/31/201723,3451,505N/A-1,468N/A
12/31/201621,4791,125N/A-1,455N/A
9/30/201620,9812,063N/A600N/A
6/30/201619,9652,057N/A1,591N/A
3/31/201619,3301,706N/A1,669N/A
12/31/201518,6951,354N/A1,748N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A215380's forecast earnings growth is above the savings rate (3.1%).

Earnings vs Market: Insufficient data to determine if A215380's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A215380's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A215380's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A215380's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A215380's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/12 06:39
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

WOOJUNG BIO, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jae Hoon ShinHanwha Investment & Securities Co., Ltd.